Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. The company is dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. and other countries for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Their research focuses on innovative mechanisms to combat cancer and improve patient outcomes.
The headquarters serves as the central hub for Karyopharm's research and development, clinical operations, commercial strategy, and corporate administration.
State-of-the-art laboratory facilities for drug discovery and development, combined with modern office spaces designed to promote collaboration and innovation.
A fast-paced, science-driven environment focused on advancing innovative cancer therapies. Employees often describe a mission-oriented culture with a strong emphasis on teamwork, scientific rigor, and patient impact.
Strategically located in the Boston-Cambridge biotech cluster, providing Karyopharm with access to world-class talent, leading research institutions, and numerous industry partners, fostering innovation and collaboration.
Karyopharm Therapeutics operates with a global reach, anchored by its U.S. headquarters for research, development, and primary commercial activities. The company is expanding its commercial and clinical presence in key international markets, notably through its European headquarters in Switzerland, and partnerships to bring its novel cancer therapies to patients worldwide. Clinical trials are often conducted across North America, Europe, and Asia-Pacific.
85 Wells Avenue, Suite 210
Newton
Massachusetts
USA
Address: Karyopharm Europe GmbH, Dammstrasse 19, CH-6300 Zug, Switzerland
To facilitate the commercialization and accessibility of Karyopharm's therapies, such as XPOVIO® (selinexor), to patients in Europe and to engage with European regulatory bodies, healthcare professionals, and key opinion leaders.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Karyopharm Therapeutics Inc.' leadership includes:
Karyopharm Therapeutics Inc. has been backed by several prominent investors over the years, including:
Karyopharm Therapeutics has actively refreshed its leadership team over the past 12 months (approx. June 2023 - June 2024), appointing 6 new executives and seeing 2 notable departures, alongside key internal transitions, to strengthen its strategic, operational, and commercial capabilities.
Discover the tools Karyopharm Therapeutics Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Karyopharm Therapeutics commonly uses the email format combining the first initial and last name. Variations might exist, but this is the most frequently observed pattern.
[first_initial][last]@karyopharm.com
Format
rpaulson@karyopharm.com
Example
85%
Success rate
Karyopharm Therapeutics Press Release • June 3, 2024
Karyopharm announced multiple presentations at the 2024 ASCO Annual Meeting, showcasing new clinical and preclinical data for its lead drug selinexor and investigational agent eltanexor across various cancer types, highlighting ongoing research and potential new applications....more
Karyopharm Therapeutics Press Release • May 20, 2024
The company reported positive topline results from the prespecified interim analysis of the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy in patients with advanced or recurrent endometrial cancer, meeting the primary endpoint of improved progression-free survival....more
Karyopharm Therapeutics Press Release • May 7, 2024
Karyopharm reported its financial results for Q1 2024, detailing XPOVIO® net product revenue, R&D investments, and operational updates. The company also highlighted key clinical advancements and upcoming milestones....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Karyopharm Therapeutics Inc., are just a search away.